Metformin reduced Long Covid: Metformin is an old... - MPN Voice

MPN Voice

10,890 members15,213 posts

Metformin reduced Long Covid

EPguy profile image
4 Replies

Metformin is an old but well established diabetes drug. This study found a substantial benefit with metformin to prevent long covid. The attached plot shows this 41% reduction.

thelancet.com/journals/lani...

And up to 63% if taken in time:

"For participants who started metformin less than four days after their COVID symptoms started, metformin decreased the risk of long COVID by 63%."

news.unchealthcare.org/2023...

--

By comparison Paxlovid was less effective in this report:

"The analysis showed that Paxlovid reduced the risk of long COVID-19 by 26% over a six-month period."

medicine.wustl.edu/news/pax...

Both studies were on VA patients but may not be comparable.

I recall reading elsewhere that metformin did not reduce the acute Covid course, while Pax is known to do that, so it could be best the protection is to take both. But this has not been tested to my knowledge.

I plan to ask my GP about having a stash just in case. Metformin is a common diabetes med to used reduce A1C.

Written by
EPguy profile image
EPguy
To view profiles and participate in discussions please or .
Read more about...
4 Replies
Solyesh profile image
Solyesh

Metformin is a very interesting drug. I had actually asked my GP about it after reading studies on its potential effects at repairing cell damage (or slowing cell death). He said the jury was still out on that and given some of MT's less popular side effects (especially gastrointestinal) that he would wait to prescribe until additional info is analyzed...then out of the blue he called me to ask if I had seen the studies on MT's potential to inhibit JAK2 activity. He pointed me to an NIH study which concluded - "In conclusion, metformin exerts multitarget antileukemia activity in MPN: downregulation of JAK2/STAT signaling and mitochondrial activity." He also sent to my MPN specialist and I'll discuss it with him at my next appointment.

ncbi.nlm.nih.gov/pmc/articl....

From another study: Recently, the phase II study Fibromet failed to demonstrate effect of MT in reversing bone marrow fibrosis in myelofibrosis. However, significant down regulation of the JAK-STAT-pathway and cytokine production were demonstrated (Campos et al, 2021).

CONCLUSION In this study we found an inverse association between MT use and risk of MPNs indicating a potential protective effect of MT on the development of MPNs. The protective effect was most pronounced for long-term use, older age (≥60 years) and for polycythemia vera and essential thrombocythemia. Whether this effect is causal should be determined interventional studies.

MPort profile image
MPort in reply toSolyesh

That's is very interesting. Thanks for sharing and please keep us updated.

EPguy profile image
EPguy in reply toSolyesh

I had seen some mention but this is nicely specific.

My focus on MT has been for potential to reduce mouth rot with Sjogren's. But these other features are popping up, thanks for the great link.

One of the prior refs has "In conclusion, metformin displayed a remarkable anti-leukemic activity" but this study is specific to MPN.

"Interestingly, combined treatment (10 mM metformin plus 300 nM ruxolitinib) completely inhibited colony formation (Fig. 2c)."

I chose the figure 2c here, among many, for its visual impact. MT worked quite well and about as well as Rux for this measure. But this was not true for everything they measured.

See next reply for another nice visual.

"Notably, a modest effect was observed with the combination of metformin and ruxolitinib, suggesting that both drugs may share some similarities in mechanisms of action in these cells."

The MT dose used "represents a pharmacological dose lower than that used for type II diabetes treatment" and using the standard dose could add effectiveness.

--

You note a 2nd study, this seems to be a real clinical study that would be neat to review.

MT-Rux
EPguy profile image
EPguy in reply toSolyesh

Another visual from the study. This tumor comprising Ba/F3 cells is supposed to represent Jak2 allele burden. Large reductions on MT.

Jak2617

Not what you're looking for?

You may also like...

New study released: Factors associated with COVID-19

We have quantified a range of clinical risk factors for death from COVID-19, some of which were not...
JT_Marlin profile image

Impact of COVID-19 infection in blood cancer patients

Post by MPN-MATE Admin » Fri Jul 10, 2020 10:17 am Morning all... :D Here is some encouraging...
socrates_8 profile image

ONS and Oxford University Covid test

Afternoon all, Hope you are all well. Just a question I would like to ask of you all. Has anyone on...
Superwoman profile image

COVID vaccines and risk of blood clots

After a careful review of the data, UK and International regulatory agencies confirmed yesterday...
Mazcd profile image
Partner

BLOOD TYPES & COVID–19 CONNECTIONS TO SEVERITY

Post by MPN-MATE Admin » Tue Oct 27, 2020 11:44 am Morning all... :D Not that I wish to be the...
socrates_8 profile image

Moderation team

Debinha profile image
DebinhaAdministrator
Mazcd profile image
MazcdPartner

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.